EQS-Adhoc: H&R GmbH & Co. KGaA: Preliminary results for Q1/2025 published

Insider information pursuant to Article 17 of the Market Abuse Regulation [MAR]

H&R GmbH & Co. KGaA: Preliminary results for Q1/2025 published

• Results in Q1-2025 slightly improved compared to previous year
• EBITDA of EUR 22.4 million (Q1-2024: EUR 21.3 million) a good 5% above the same quarter of year 2024

Salzbergen, Germany, April 30, 2025. H&R GmbH & Co. KGaA (H&R KGaA for short; DE000A2E4T77) achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as amortization, depreciation and impairment losses and reversals of impairment losses on intangible assets and property, plant and equipment) of EUR 22.4 million in the first quarter of 2025 (Q1/2024: EUR 21.3 million), slightly above the level of the same quarter of the previous year, according to preliminary calculations.

Based on slightly higher sales revenue compared to the previous year, the improved performance is reflected across all earnings levels. EBIT amounted to EUR 7.7 million (Q1/2024: EUR 6.8 million) and earnings before taxes (EBT) to EUR 4.7 million (Q1/2024: EUR 3.6 million). At the bottom line, the Group achieved an improved result attributable to its shareholders of EUR 1.9 million compared to the same quarter of the previous year (Q1/2024: EUR 1.5 million). This was achieved with sales revenues of EUR 345.8 million, around 2.6% more than in the previous year (Q1/2024: EUR 337.0 million). Overall, we recorded robust demand in the first quarter of 2025. Product prices and quotations were also in line with our expectations at the start of the year. The latter brightened somewhat compared to the end of the previous year and made it easier for us to negotiate prices with buyers in our customer industries to some extent.

Segment ChemPharm Refining significantly improved

The development of the segments presents a different picture than a year ago. While the Group's international business was particularly impressive in Q1/2024, the locations of our ChemPharm SALES segment fell short of the same quarter in 2024 at the start of 2025. At EUR 123.7 million, the segment slightly exceeded the previous year's figure in terms of sales revenue (Q1/2024: EUR 122.9 million), while the EBITDA result of EUR 10.9 million for the previous year was not achieved in the first quarter of 2025 at EUR 9.7 million. 

By contrast, the production sites in the ChemPharm REFINING segment performed more positively. They sold stable to slightly improved volumes overall in the first quarter of 2025. Sales revenues increased to EUR 217.4 million (Q1/2024: EUR 206.4 million). The segment's EBITDA in the first quarter of 2025 also indicates an improved performance: It amounted to EUR 13.9 million (Q1/2024: EUR 10.5 million).

The PLASTICS segment was fully impacted by the weak automotive industry in the first quarter of 2025: The companies of the GAUDLITZ Group did not achieve positive EBITDA in the first quarter of 2025, but instead burdened the consolidated result with a loss of EUR -0.4 million (Q1/2024: EUR 0.4 million). Sales revenues also declined, from EUR 12.3 million in the previous year to EUR 9.6 million in Q1/2025.

Cash flow in Q1/2025 reflects development of current assets

Operating cash flow in the first quarter of 2025 fell to EUR -8.1 million (Q1/2024: EUR 11.4 million). This was primarily due to reporting date-related changes in net working capital for the REFINING segment, which was characterized by a higher level of receivables on the one hand and a simultaneous reduction in liabilities on the other as of March 31, 2025. Free cash flow also closed significantly lower at EUR -17.7 million (Q1/2024: EUR -0.2 million).

Equity base remains solid

Total assets decreased slightly to EUR 1,011.4 million at the end of the first quarter of 2025 (31/12/2024: EUR 1,014.8 million). The Group's equity amounted to EUR 466.0 million as at the reporting date (31/12/2024: EUR 468.6 million). The ratio was 46.1% (31/12/2024: 46.2%).

Published guidance remains in focus

Based on Q1/2025, H&R is on track overall with the full-year guidance for 2025 communicated in the 2024 Annual Report, with a range of EUR 85.0 million to EUR 100.0 million.

For a complete presentation of the business development including segment reporting and the quarterly financial statements, H&R KGaA refers to the Quarterly Statement 1/2025 to be published on May 15, 2025.

Contact:
H&R GmbH & Co. KGaA, Head of Investor Relations / Communication, Ties Kaiser
Neuenkirchener Straße 8, 48499 Salzbergen
Phone.: +49 40 43218-321, Fax: +49 40 43218-390
Mail: ties.kaiser@hur.com
www.hur.com

H&R GmbH & Co. KGaA:

Listed in the Prime Standard of the Frankfurt Stock Exchange, H&R GmbH & Co. KGaA is a specialty chemicals company active in the development and manufacture of chemical-pharmaceutical specialty products based on fossil, bio-based, synthesized and recycled hydrocarbons and in the production of precision plastic parts.

Forward-looking statements and forecasts:

This insider information pursuant to Article 17 of the Market Abuse Regulation [MAR] contains forward-looking statements. The statements are based on the current estimates and forecasts by the Management Team and the information available to it at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this insider information pursuant to Article 17 of the MAR.